Gene link to higher rates of bowel cancer in men

June 1, 2012
Gene link to higher rates of bowel cancer in men

(Medical Xpress) -- Scientists have shown for the first time that one of the sex chromosomes is involved in the development of a cancer that can afflict both genders, according to a Cancer Research UK-funded study in Nature Genetics. The finding may help explain why men have higher rates of bowel cancer than women.

The international collaboration - led by The Institute of Cancer Research (ICR), the University of Oxford and Edinburgh University – was searching for changes to the DNA code that increase the risk of bowel cancer. For the first time, the scientists identified an alteration on the x-chromosome, one of two chromosomes that determine gender.

The ‘faulty’ region on the x-chromosome is linked to lower levels of a gene called SHROOM2 that controls how cells develop and take shape. Mutations in this gene have previously been linked to cancer.

The scientists have suggested that in women, the ‘faulty’ x-chromosome version is hidden by a normally-functioning version. But in men, who only have one copy of the x-chromosome, there is no normal version to mask this ‘faulty’ copy.

Co-lead researcher Professor Richard Houlston from The Institute of Cancer Research said: “To our knowledge, this is the first time that anyone has shown that one of the is involved in the development of a cancer that can afflict both sexes. This may help explain why bowel cancer is slightly more common in men. Ultimately, it could also help us target screening to those who are more at risk of the disease.”

The discovery of the x-chromosome link, along with a further two risk variants, brings the total number of regions on the genome found to increase the risk of bowel cancer to 20.  

To identify these genetic alterations the researchers studied SNPs (single nucleotide polymorphisms) - pieces of DNA that vary between individuals – from five previous international studies, looking for SNPs that were more common in cancer cases than healthy individuals.

The second variant found in this study is within the CDKN1A gene on chromosome 6. CDK1NA codes for a protein that is a key controller of a number of tumour suppressor pathways in the cell. It also blocks the creation of new strands of DNA which is needed in cancer cells as they grow and divide.   

The third variant discovered is located on chromosome 11, within a gene called POLD3. This gene plays a key role in two pathways that repair DNA damage, and which are defective in some bowel cancers.   

Bowel cancer is the third most common cancer in the UK - each year around 41,000 people are diagnosed with the disease, around 22,700 men and 18,400 women.  

Dr. Lesley Walker, director of cancer information at Cancer Research UK, said: “Cancer Research UK funded scientists have led the world in discovering that increase the risk of bowel cancer. This research adds to this understanding and shows how a range of genes could be behaving in , potentially leading to new treatments for the disease.”  

Explore further: Prostate cancer early warning protein detected

More information: Dunlop, M.G. et al Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk Nature Genetics (2012)

Related Stories

Prostate cancer early warning protein detected

May 31, 2012
(Medical Xpress) -- Scientists at the University have discovered a protein, only present in prostate cancer cells, that could be used as a marker to detect early signs of the disease.     

Poor men more likely to die from bowel cancer

November 7, 2011
(Medical Xpress) -- Deprived men are more likely to die from bowel cancer than men from the most affluent section of society, new research presented at the NCRI Cancer Conference in Liverpool this week shows.

Poor public awareness of bowel cancer

August 23, 2011
Britons have very low awareness of the signs and symptoms of bowel cancer – the third most common cancer in the UK and second largest cause of cancer deaths each year, new research shows.

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.